Diagnosis, testing and biomarkers in the individualisation of patient care with FGFR mutated bladder cancer

Bookmark and Share
Published: 18 Feb 2021
Views: 977
Rating:
Save
Prof Andrea Necchi and Prof Eva Compérat

Prof Andrea Necchi (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy) and Prof Eva Compérat (Medical University of Vienna, Vienna, Austria) discuss diagnosis, testing and biomarkers in the individualisation of patient care with FGFR mutated bladder cancer.

Initially, they discuss the currents diagnostic techniques in use and new data from ASCO GU 2021 regarding FGFR mutated bladder cancer. They then talk about how pathologists and medical oncologists can work together effectively to diagnose and treat patients with FGFR bladder cancer.

They further talk about the targeted treatment options for these patients from ASCO GU 2021 and the future of FGFR mutated bladder cancer treatment and diagnosis. They mention studies regarding enfortumab vedotin in metastatic urothelial carcinoma.

In the end they talk about Nectin-4 expression and germline alterations for high-risk bladder cancer patients.

This programme has been supported by an unrestricted educational grant from Janssen.